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Abstract
Background:  Quinolone resistance in Enterobacteriaceae  results mainly from mutations in type II DNA
topoisomerase genes and/or changes in the expression of outer membrane and efflux pumps. Several recent
studies have indicated that plasmid-mediated resistance mechanisms also play a significant role in fluoroquinolone
resistance, and its prevalence is increasing worldwide. In China, the presence of the qnr gene in the clinical isolates
of Enterobacteriaceae has been reported, but this transmissible quinolone resistance gene has not been detected
in strains isolated singly from pediatric patients. Because quinolones associated with a variety of adverse side
effects on children, they are not authorized for pediatric use. This study therefore aimed to investigate the
presence of the qnr gene in clinical isolates of E. coli and K. pneumoniae from pediatric patients in China.
Methods: A total 213 of non-repetitive clinical isolates resistant to ciprofloxacin from E. coli and K. pneumoniae
were collected from hospitalized patients at five children's hospital in Beijing, Shanghai, Guangzhou, and
Chongqing. The isolates were screened for the plasmid-mediated quinolone resistance genes of qnrA, qnrB, and
qnrS by PCR. Transferability was examined by conjugation with the sodium azide-resistant E. coli J53. All qnr-
positive were analyzed for clonality by enterobacterial repetitive intergenic consensus (ERIC)-PCR.
Results: The study found that 19 ciprofloxacin-resistant clinical isolates of E. coli and K. pneumoniae were positive
for the qnr gene, and most of the qnr positive strains were ESBL producers. Conjugation experiments showed
that quinolone resitance could be transferred to recipients. Apart from this, different DNA banding patterns were
obtained by ERIC-PCR from positive strains, which means that most of them were not clonally related.
Conclusion: This report on transferable fluoroquinolone resistance due to the qnr gene among E. coli and K.
pneumoniae strains indicated that plasmid-mediated quinolone resistance has emerged in pediatric patients in
China.
Published: 22 May 2008
BMC Infectious Diseases 2008, 8:68 doi:10.1186/1471-2334-8-68
Received: 9 November 2007
Accepted: 22 May 2008
This article is available from: http://www.biomedcentral.com/1471-2334/8/68
© 2008 Wang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2008, 8:68 http://www.biomedcentral.com/1471-2334/8/68
Page 2 of 6
(page number not for citation purposes)
Background
Quinolone resistance in Enterobacteriaceae results mainly
from mutations in type II DNA topoisomerase genes[1]
and/or changes in the expression of outer membrane and
efflux pumps[2]. Recently, studies have shown that plas-
mid-mediated resistance mechanisms also play a signifi-
cant role in fluoroquinolone resistance, and its prevalence
is increasing worldwide [3]. qnrA is the plasmid-mediated
quinolone resistance gene encoding a 218 amino acid
protein of the pentapeptide family that protects DNA
gyrase from quinolone inhibition[4]. The new plasmid-
mediated quinolone resistance genes, qnrB and qnrS, have
been reported in clinical isolates[5,6]. In China, the pres-
ence of the qnr  gene in clinical isolates of Enterobacte-
riaceae  from Shanghai [7] and Anhui[8] has been
reported, but this transmissible quinolone resistance gene
has not been detected in strains isolated singly from pedi-
atric patients. Because quinolones associated with a vari-
ety of adverse side effects on children, they are not
authorized for pediatric use. Therefore, the objective of
this study was to screen for the presence of the qnr gene in
clinical ciprofloxacin-resistant isolates of Escherichia coli




Three hundred thirty-five Escherichia coli and 392 Klebsiella
pneumoniae non-replicate clinical isolates were collected
from five children's hospitals located in Beijing, Shanghai,
Guangzhou, and Chongqing from January 2005 to
December 2006. Each hospital is a general pediatric hos-
pital locally affiliated to a university. The isolates were
identified at the participating hospitals by routine meth-
odology at each laboratory, and then were transported to
Beijing Children's Hospital for further analysis. All iso-
lates were screened for ciprofloxacin resistance by disk
method according to the criteria of NCCLS [9]. The
screening showed 146 Escherichia coli and 67 Klebsiella
pneumoniae  isolates were ciprofloxacin-resistant. Addi-
tional strain used was E. coli J53AzR(resistant to azide) as
a recipient of the conjugation experiment
Screening for the qnrAM, qnrB, and qnrS gene in clinical 
strains
The 213 ciprofloxacin-resistant strains of E. coli and K.
pneumoniae were screened by multiplex PCR amplification
of qnrA, qnrB, and qnrS as previously described[10]. Colo-
nies were transferred to an Eppendorf tube filled with
water and boiled to prepare DNA templates for PCR. The
primers used for qnrA, qnrB, and qnrS were as follows: '5-
ATTTCTCACGCCAGGATTTG-3' and 5'-GATCGGCAAAG-
GTTAGGTCA-3' for qnrA  for a 516-bp product, 5'-
GATCGTGAAAGCCAGAAAGG-3' and 5'-ACGATGCCT-
GGTAGTTGTCC-3' for qnrB for a 469-bp product, and 5'-
ACGACATTCGTCAACTGCAA-3' and 5'-TAAATTGGCAC-
CCTGTAGGC-3' for qnrB for a 417-bp product. The proto-
col for the PCR condition was: 94°C for 45 s, 53°C for 45
s, and 72°C for 60 s, with a cycle number of 32, and with-
out DNA template as negative controls in each run.
Amplification products were provisionally identified by
their size in ethidium bromide-stained agarose gels. The
positive amplified PCR product for qnrA, qnrB, and qnrS
was analyzed with an automated DNA sequencing system.
The results of DNA sequences were compared with the
BLAST online search engine from GenBank at the
National Center for Biotechnology Information Web site:
http://www.ncbi.nlm.nih.gov/blast.
Conjugation experiments
All positive qnr  strains were tested for transferred qui-
nolone resistance by conjugation experiments carried out
in Luria Broth with E. coli J53AzR as the recipient. The cul-
tures of donor and recipient cells were incubated via shak-
ing at 37°C in logarithmic phase, and then 0.5 mL of both
cultures was added to 4 mL of fresh LB and incubated
overnight without shaking. Transconjugants were selected
on trypticase soy agar (TSA) plates with sodium azide
(100 μg/mL from Sigma Chemical Co., St. Louis, MO) for
counter selection and ampicillin (100 μg/mL from Oxoid)
to select for plasmid-encoded resistance. To determine if
quinolone resistance was cotransferred, colonies were rep-
lica-plated onto TSA with and without ciprofloxacin (0.06
μg/mL; Oxoid). The PCR experiments confirmed
transconjugants carrying the same qnr  gene as their
donors.
Antimicrobial susceptibility profiles
MICs for the 19 positive qnr isolates, recipient (J53 AzR),
and transconjugant strains were measured by agar dilu-
tion in accordance with the guidelines of the NCCLS. The
antimicrobials tested were ampicillin/clavulanic acid,
cefotaxime, ceftazidime, cefoperazone, cefoxitin,
cefepime, aztreonam, imipenem, ciprofloxacin, ofloxacin,
amikacin, and gentamicin (Oxoid, England). Quality con-
trol was performed by testing Escherichia coli ATCC25922.
Isolates which showed MICs ≥ 2 μg/ml for cefotaxime
and/or ceftriaxone and/or ceftazidime and/or aztreonam
were considered as ESBL producers. The ESBL phenotype
was confirmed by using clavulanic acid (Oxoid, England)
according to the manufacturer's recommendation.
Strain typing by ERIC-PCR
The 11 positive qnr Escherichia coli strains and 8 positive
qnr Klebsiella pneumoniae strains were typed by ERIC-PCR.
Total DNA from qnr  positive isolates was analyzed by
ERIC sequence PCR with the ERIC1R (5'-ATGTAAGCTC-
CTGGGGATTCAC-3') and ERIC2 (5'-AAGTAAGTGACT-
GGGGTGAGCG-3') primers, and PCR was performed as
previously described [11]. ERIC-PCR was performedBMC Infectious Diseases 2008, 8:68 http://www.biomedcentral.com/1471-2334/8/68
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briefly using the following program parameters: denatur-
ation at 94°C for 1 s, annealing at 52°C for 10 s, and
extension at 72°C for 35 s for 30 cycles, followed by a
final extension at 72°C for 4 min. Amplicons were sepa-
rated on a 1.5% agarose gel containing ethidium bromide
(5  μg/mL) at 60 V for 3 hours. The gels were photo-
graphed and digitized. Isolates were considered different
if their profiles differed by two or more bands[12].
Results
Screening for the qnr genes
Nineteen ciprofloxacin-resistant clinical isolates, includ-
ing eleven E. coli and eight K. pneumoniae strains, were
positive for the qnr gene. Table 1 shows the clinical char-
acteristics of these isolates and the distribution of qnrA,
qnrB, or qnrS. The sequences of qnr genes were all identical
to those of qnrA (EU195836), qnrB (EU443840), and qnrS
(EU391634) with GenBank, respectively.
Conjugation and antimicrobial susceptibility
Quinolone resistance could be transferred by conjugation
in two of eight of Klebsiella pneumoniae qnr-positive
donors. One qnrB-positive and one qnrS-positive
transconjugant were obtained. PCR experiments con-
firmed that the transconjugants harbored the same qnr
gene as their donors. Table 2 shows the susceptibilities of
the qnr-positive clinical isolates for the selected antibiot-
ics. Most isolates were resistant to cephalosporin, aztre-
onam, and aminoglycosides, whereas all of the strains
were susceptible to imipenem. Eight of eleven qnr positive
isolates of Escherichia coli and all eight qnr positive isolates
of Klebsiella pneumoniae were phenotypic ESBL producers,
respectively. Antibiotic susceptibilities for the two
transconjugants showed that the ciprofloxacin resistance
MIC value increased 32- and 1024-fold, respectively;
meanwhile, oflaxacin resistance MIC value increased 2-
and 32-fold, respectively.
Strain typing by ERIC-PCR
The positive qnr isolates of E. coli, and K. pneumoniae
showed different DNA banding patterns, indicating that
they were not clonally related.
Discussion
This study is the first report on the presence of the qnr gene
in clinical isolates from pediatric patients in China. The
prevalence rates of qnr among ciprofloxacin-resistant iso-
lates of E. coli and K. were 7.5% (11 of 146), and 11.9%
(8 of 67), respectively. The qnr  rate in isolates of
Escherichia coli analyzed in this study was similar to the
prevalence in Shanghai, China, wherein there was 8% (6
of 78 strains) of ciprofloxacin-resistant clinical isolates of
E. coli [7]. These rates are lower than the prevalence of
qnrA  detected among ceftazidime-resistant or cipro-
Table 1: Clinical characteristics and qnr genotype of the qnr-positive isolates
Number of Strains Specimen Sex Age Diagnoses qnr ESBL
E. coli
05B239 sputum m 2 months Pneumonia qnrA, qnrB, qnrS -
05C2795 sputum f 15 days Pneumonia qnrA +
05G1844 vulvar secretions f 5 years Vulvitis qnrA, qnrS -
05G1889 urine m 2 months Hydronephrosis qnrA, qnrB +
05SB14 sputum f 24 days Pneumonia qnrS +
05SB25 urine m 5 months UTIa qnrA, qnrB +
05SB47 tracheal f 12 months Pneumonia qnrA, qnrB +
06G60 blood m 3 years ALLb qnrA +
06G62 sputum f 24 days Pneumonia qnrS +
06G99 sputum f 4 months Pneumonia qnrA, qnrB -
06SA30 sputum f 2 months Pneumonia qnrS +
K. pneumoniae
05C2978 sputum m 9 months Pneumonia qnrB +
05G44 sputum f 1 months Pneumonia qnrB +
05SA32 sputum f 21 months Pneumonia qnrS +
06B295 sputum m 11 days Pneumonia qnrB +
06B700 urine f 4 years UTIa qnrB +
06C3889 sputum f 4 days Pneumonia qnrS +
06C5524 sputum f 3 months Pneumonia qnrB +
06SB60 sputum m 3 months Pneumonia qnrS +
aUTI, Urinary tract infection;
bALL, Acute lymphoblastic leukemia.BMC Infectious Diseases 2008, 8:68 http://www.biomedcentral.com/1471-2334/8/68
Page 4 of 6
(page number not for citation purposes)
floxacin-resistant strains (24%) of Enterobacter  in
USA[13]. Among the three groups of the qnr gene, qnrA
was more prevalent (8 of 11) in Escherichia coli strains,
whereas qnrB was more prevalent (5 of 8) in the Klebsiella
pneumoniae isolates. As there are differences in the criteria
for testing strains, evaluating the precise prevalence of
plasmid-mediated quinolone resistance was difficult.
It should be noted that all the positive qnr isolates were
distributed in pediatric patients: more than one-third
were isolated from children younger than one year of age,
and nearly one-fourth were isolated from neonates.
Because of the variety of adverse side effects of quinolones
in children, hospitals are not advised to use them on chil-
dren. In China, quinolones are not used on children
younger than 16 years old. Presumably, the source of the
qnr gene might not be directly associated with the selective
pressure caused by the quinolones used in pediatrics, but
it could be related to horizontal transmission from adults
or other reservoir. Recent findings showed that these
genes come from environmental gram-negative bacterial
species, such as Shewanella algae, the progenitor of the
qnrA genes [14], and Vibrio splendidus or Aeromonas spp.,
the progenitor of qnrS genes[15,16]. This shows that the
aquatic environment is an important reservoir of novel
antibiotic resistance determinants. Quinolones are anti-
microbial agents extensively used in aquaculture and are
stable molecules in water [17]. Exposure to lower concen-
trations of quinolones increases the chance for seletion of
resistance. Therefore, they may be the source of an impor-
tant driving force for the selection of quinolone resistance.
Another study showed that qnrS  genes were identified
from E. coli and E. cloacae isolated from zoo animals in
Japan, suggesting that animals could be a potential reser-
voir of quinolone-resistant bacteria[18]. Quinolones are
the most common antimicrobial used in animals, the
annual consumption of which is about 470 tons in China
[19]. In the present study, more than two-thirds of qnr
positive strains were isolated from sputum sample. These
strains may be confined in children's respiratory tract,
which come from the contaminated environment.
This study showed that most qnr  positive strains were
ESBL producers, indicating the relationship between the
Table 2: Resistance profiles of the qnr positive strains and transconjugants
Strain MIC(μg/ml)
AMCa CFP CTX CAZ FOX FEP IPM/CS ATM AMK GEN CIP OFX
E. coli
05B239 32 > 512 512 32 32 512 0.25 64 4 128 64 32
05C2795 128 512 64 256 512 16 0.5 256 16 256 16 32
05G1844 32 512 64 8 32 8 0.125 16 4 128 64 32
05G1889 32 512 > 512 32 32 128 0.25 32 8 128 64 64
05SB14 16 > 512 128 8 32 16 0.125 8 8 256 64 16
05SB25 32 > 512 > 512 128 32 128 0.125 64 4 128 64 32
05SB47 32 > 512 > 512 512 16 > 512 0.25 256 8 128 256 64
06G60 32 512 512 32 16 128 0.25 64 4 128 32 16
06G62 16 512 512 8 32 32 0.125 8 8 128 64 32
06G99 64 > 512 > 512 512 512 128 0.25 256 4 128 64 64
06SA30 32 512 > 512 8 32 32 0.25 16 16 256 4 32
K. pneumoniae
05C2978b 32 128 128 512 16 64 0.125 128 4 32 256 128
05SA32b 32 256 256 512 16 128 0.125 128 8 2 4 8
05G44 128 > 512 > 512 > 512 512 512 1 512 8 32 4 4
06B295 32 > 512 128 64 16 64 1 64 8 2 4 8
06B700 32 512 512 256 256 128 0.25 128 8 128 32 8
06C3889 32 > 512 256 512 32 64 0.125 256 > 512 > 512 256 256
06C5524 32 256 128 512 16 64 0.5 512 > 512 512 64 32
06SB60 32 > 512 > 512 64 32 512 0.25 256 4 128 4 32
Recipients
J53 16 2 0.125 0.25 2 1 0.0625 4 8 0.25 0.125 0.25
Transconjugants
Tc 05C2978c 32 128 128 512 64 32 0.125 128 8 512 128 8
Tcb 05SA32c 32 512 512 512 128 256 0.25 128 16 128 4 0.5
a AMC, amoxicillin/clavulanic acid; CFP, cefoperazone; CTX, cefotaxime; CAZ, cefotaxime; FOX, cefoxitin; FEP, cefepime; IPM/CS, imipenem/
cilastatin; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; OFX, ofloxacin.
b domor;
c Tc, transconjugantsBMC Infectious Diseases 2008, 8:68 http://www.biomedcentral.com/1471-2334/8/68
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qnr gene and ESBL. Other studies have shown that several
qnrA-positive isolates express ESBL [7,20,21]. A qnrS gene
on a plasmid encoding ESBL in a K. pneumoniae strain also
has been reported in Taiwan, China [22]. Therefore, the
fact that expanded-spectrum cephalosporins are widely
used among Chinese children may also contribute to the
presence of the qnr gene. Another study by the present
researchers suggested that third-generation cepha-
losporins are commonly used in pediatric patients (data
not published).
Conjugation experiments showed that only two qnr-posi-
tive K. pneumoniae strains were able to transfer the qnr
gene in transconjugants. This transferability was similar to
the findings of other studies, which also showed that not
all  qnr-positive strains were able to transfer quinolone
resistance [23,24]. The lower resistance to ciprofloxacin
and oflaxacin in these two transconjugants than their
donor strains may imply the presence of additional chro-
mosomal resistance mutations. The results of ERIC-PCR
showed that the positive qnr strains have different types of
DNA band, thereby suggesting that the qnr in clinical iso-
lates was not caused by the spread of identical strains.
Although the number of data points is limited, this report
confirms the spread of the plasmid-mediated quinolone
resistance qnr gene in E. coli and K. pneumoniae strains iso-
lated from pediatric patients. Still, however, further
research is needed to understand the influence of this
gene on quinolone resistance for pediatric patients in
China.
Conclusion
The prevalence rates of qnr among the clinical isolates of
ciprofloxacin resistance in E. coli and K. pneumoniae were
7.5% (11 of 146) and 11.9% (8 of 67), respectively. The
transferability of fluoroquinolone resistance because of
the  qnr  gene among E. coli and  K. pneumoniae strains
shows that plasmid-mediated quinolone resistance has
been spread in pediatric patients in China.
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